Prospective Huntington At Risk Observational Study
- Conditions
- Huntington Disease
- Registration Number
- NCT00052143
- Lead Sponsor
- Huntington Study Group
- Brief Summary
The purpose of this study is to define the natural history and experiences of people who are at risk for developing Huntington's disease but who do not know their genetic status.
- Detailed Description
Huntington's disease (HD) is a genetic disease characterized by changes in movement and behavior. To date, little research has been done on individuals who are at risk for developing the disease. PHAROS is an observational study designed to monitor people who are at risk for developing HD, and to survey their attitudes and beliefs about their "at-risk" status. Investigators hope this study will help answer some important questions about HD, such as: 1.) What are the earliest signs of HD and when do they start? 2.) How accurate are the measures that physicians use in detecting the onset of HD? 3.) What factors influence the age at which a person carrying the HD gene develops the illness? and 4.) In a group of people at risk for HD, how many will develop signs of the illness over a minimum three-year period of observation?
Participants in the study will be evaluated every 9 months (for 5 years) using the Unified Huntington's Disease Rating Scale (UHDRS)--a clinical tool which looks at movement, psychological and behavioral function. The participants will also be asked to complete surveys about their mood, life events, and attitudes or beliefs about being at risk for HD. A blood sample, taken at the beginning of the study, will be confidentially tested to determine if the participant has the abnormal gene for HD. Neither the participant nor any of the PHAROS physicians or coordinators will learn the results of individual gene tests.
The scientists hope that this study will provide essential information for future trials of experimental drugs for HD.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 1001
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (42)
University of Alabama
πΊπΈBirmingham, Alabama, United States
Mayo Clinic Arizona
πΊπΈPhoenix, Arizona, United States
University of California at San Diego
πΊπΈLa Jolla, California, United States
UCLA School of Medicine
πΊπΈLos Angeles, California, United States
University of California, Davis
πΊπΈSacramento, California, United States
Colorado Neurological Institute
πΊπΈEnglewood, Colorado, United States
University of Connecticut
πΊπΈHartford, Connecticut, United States
Institute for Neurodegenerative Disorders
πΊπΈNew Haven, Connecticut, United States
University of Miami School of Medicine
πΊπΈMiami, Florida, United States
University of South Florida
πΊπΈTampa, Florida, United States
Scroll for more (32 remaining)University of AlabamaπΊπΈBirmingham, Alabama, United States